glp-1 news insurers Insurance companies scrambling to support need for drugs - Insurance Rising Costs Lead Insurers to

Some potential future developments in continuous glucose monitoring include: Smaller and more discreet sensors As technology progresses, CGM sensors are likely to become even smaller and more discreet, offering enhanced comfort and wearability

Safety concerns have surrounded the drug since it was first developed in the US in the 1990s, particularly its potential to induce melanoma, the deadliest form of skin cancer

Prescribing it specifically for weight loss would be considered off-label use

Taken together, these moves suggest Nestl is prioritizing fewer, clearer growth platforms, and ones tied to culinary credibility, daily rituals and higher perceived value instead of stretching itself across too many categories at once

Thus, the insulin receptor loses its sensitivity towards insulin [3]

Developments in Plant and Soil Sciences (ed